Cancer-Related End-Stage Renal Disease Incidence Increasing
From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study published. (Source: CancerNetwork)
Source: CancerNetwork - April 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Cancer Complications Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA ® (pembrolizumab)
Dateline City: WILMINGTON, Del.& KENILWORTH, N.J.Clinical Program Now Includes Seven Registrational Trials Across Five Tumor TypesWILMINGTON, Del.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung can...
Source: Merck.com - Corporate News - March 31, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news

G-BA confirms additional benefit of Eisai ’s Kisplyx to treat advanced RCC
The German Federal Joint Committee (G-BA) has confirmed the additional benefit of Eisai ’s in-house developed anti-cancer agent, Kisplyx (lenvatinib mesylate), to treat advanced renal-cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 31, 2017 Category: Pharmaceuticals Source Type: news

Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
(University of Texas M. D. Anderson Cancer Center) Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news

Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Make the Diagnosis: Risk-revealing Rash
(MedPage Today) -- Case Findings: A 60-year-old woman presents with a new non-pruritic rash and muscle weakness. She reports difficulty carrying her groceries and getting up from the couch. A physical examination reveals an erythematous rash on her face, back, and neck, and violaceous papules on her eyelids and the joints of her fingers. Laboratory tests reveal positive antinuclear antibodies and an elevated serum creatinine kinase. This condition is associated with an increased risk of malignancy including renal cell carcinoma, leukemia, thyroid cancer, and ovarian cancer. What is your diagnosis? (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 20, 2017 Category: Hematology Source Type: news

"Richness of Choices" Available in Kidney Cancer, But Patient Selection Is Key
Between the frontline and second-line settings, there are multiple treatment options available for patients with renal cell carcinoma (RCC), but it is critically important for oncologists to decide on an agent with a patient ’s characteristics—and goals—in mind, according to Eric Jonasch, MD.03/11/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 10, 2017 Category: Urology & Nephrology Source Type: news

Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1-Positive mRCC
This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2017 Category: Cancer & Oncology Authors: David F. McDermott, MD Tags: Videos Genitourinary Cancers Source Type: news

Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1 –Positive mRCC
This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2017 Category: Cancer & Oncology Authors: David F. McDermott, MD Tags: Videos Genitourinary Cancers Source Type: news

Medical News Today: Investigational drug shows promise for hard-to-treat renal cancer
Savolitinib seems to halt tumor progression in some people with papillary renal cell carcinoma - a form of kidney cancer - according to new study results. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 1, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Vorinostat Plus Bevacizumab Had Activity in Previously Treated RCC
Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

First Look at Combo With Immunotherapy in Untreated mRCC First Look at Combo With Immunotherapy in Untreated mRCC
The immunotherapy atezolizumab in combination with bevacizumab had some'provocative'phase 2 results in untreated, advanced renal cell carcinoma.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 27, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Your participation in this research project can help ensure that the company ’s brochure and other materials are relevant to patients
A major pharmaceutical manufacturer has commissioned market research to help improve its communications directed toward Renal Cell Carcinoma (RCC) patients.Your participation in this research project can help ensure that the company’s brochure and other materials are relevant to patients’ concerns and expressed in a clear and comprehensible way.Fieldwork, an independent healthcare research and consulting firm located in the U.S., has been engaged to conduct these research interviews on pharmaceutical manufacturer’s behalf. The research project consists of a one-time telephone interview lasting 60 minutes....
Source: Kidney Cancer Association - February 23, 2017 Category: Urology & Nephrology Source Type: news

Argos says independent committee predicts trial failure
Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail.02/24/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2017 Category: Urology & Nephrology Source Type: news

Argos says independent committee predicts trial failure, shares slump
(Reuters) - Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Does Active Surveillance Benefit Patients With Metastatic RCC?
Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities. (Source: CancerNetwork)
Source: CancerNetwork - February 22, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium News Renal Cell Carcinoma Source Type: news

Clinical Data From Phase I Dose-Escalation Study Of NKTR-214
Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.02/22/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 21, 2017 Category: Urology & Nephrology Source Type: news

Computer-Aided Evaluation of Tumor Response Could Benefit RCC Patients
Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium News Renal Cell Carcinoma Source Type: news

Active Surveillance in Small Renal Masses
In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2017 Category: Cancer & Oncology Authors: Phillip M. Pierorazio, MD Ridwan Alam Tags: ASCO Genitourinary Cancers Symposium Renal Cell Carcinoma Source Type: news

Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 18, 2017 Category: Pharmaceuticals Source Type: news

Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 18, 2017 Category: Pharmaceuticals Source Type: news

Pathology Aids in Diagnosis of Hereditary Leiomyomatosis, RCC
Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Long-Term RCC Control With Immunotherapy, Despite Early Discontinuation
Immunotherapy offers durable responses lasting more than 6 months after treatment discontinuation for some patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium News Renal Cell Carcinoma Source Type: news

Antibiotics May Damper Effect of PD-1/PD-L1 Blockade
(MedPage Today) -- Worse PFS in metastatic renal cell carcinoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 14, 2017 Category: Hematology Source Type: news

Genitourinary Cancers Symposium (GUCS) 2017
In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.02/14/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 14, 2017 Category: Urology & Nephrology Source Type: news

Some Stop Immunotherapy, Still Have Controlled Cancer Some Stop Immunotherapy, Still Have Controlled Cancer
In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Do Antibiotics Impair Efficacy of Immunotherapy in Kidney Cancer?
Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Genitourinary Cancer Symposium News Renal Cell Carcinoma Source Type: news

Sunitinib Breaks Feasible for Treatment-Naive Metastatic RCC
Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy. (Source: CancerNetwork)
Source: CancerNetwork - February 3, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Your NEJM Group Today: Renal-Cell Carcinoma Clinical Pearls / Withhold Thrombolysis in Thrombectomy? / California Geriatrician Opportunity (FREE)
By the Editors Here's what we chose today from NEJM Group:NEJM Resident360: Clinical Pearls: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 2, 2017 Category: Primary Care Source Type: news

Certain Toxicities Could Be Correlated With mTOR Efficacy in Metastatic RCC
A study has shown a link between metabolic toxicities and the efficacy of mTOR inhibitors for the treatment of metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - January 22, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

ALK1/VEGF Combo Active in Advanced RCC
An early study looking at the combination of the ALK1 inhibitor dalantercept plus axitinib showed clinical activity in patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - January 8, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

NICE approves everolimus for advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2017 Category: Drugs & Pharmacology Source Type: news

Sorafenib Dose Escalation Not Supported in Most Untreated RCC Patients
Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients. (Source: CancerNetwork)
Source: CancerNetwork - December 27, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers Kidney Cancer News Renal Cell Carcinoma Source Type: news

Does IL-2 Still Have a Role in Cancer Immunotherapy?
Howard L Kaufman discusses the continuing role of high dose interleukin (HD IL-2), an approved therapy for the treatment of metastatic renal cell carcinoma (mRCC)...12/16/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 16, 2016 Category: Urology & Nephrology Source Type: news

Rotating Pazopanib and Everolimus No Extra Help in Renal Cancer Rotating Pazopanib and Everolimus No Extra Help in Renal Cancer
Alternating treatment with pazopanib and everolimus offers no advantages over continuous pazopanib in patients with metastatic clear cell renal cell cancer, according to Dutch researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The Contemporary Role of Radical Nephrectomy for RCC The Contemporary Role of Radical Nephrectomy for RCC
This study examined the role of tumor size and histological characteristics to determine when sampling is warranted.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Everolimus, CB-839 Combination Active in Advanced RCC
The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers Kidney Cancer News Renal Cell Carcinoma Source Type: news

Cabozantinib Superior to Sunitinib for Metastatic RCC Cabozantinib Superior to Sunitinib for Metastatic RCC
Cabozantinib provides significantly better progression-free survival (PFS) and objective response rates (ORR) in patients with metastatic renal cell carcinoma (RCC) of poor or intermediate risk, according to results from the Alliance A031203 CABOSUN trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Kidney Cancer Highlights of 2016
This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more. (Source: CancerNetwork)
Source: CancerNetwork - November 28, 2016 Category: Cancer & Oncology Authors: Cancer Network Editors Tags: Renal Cell Carcinoma Source Type: news

Early Intervention Important for Sunitinib-Related Hypertension in RCC
Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control. (Source: CancerNetwork)
Source: CancerNetwork - November 26, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Non-Aspirin NSAID Use Associated With Shorter Survival in Metastatic RCC
Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis. (Source: CancerNetwork)
Source: CancerNetwork - November 21, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Renal Cell Carcinoma Source Type: news

New Agents in Advanced RCC Offer Novel Combinations, Sequences
With a number of therapies now available for treatment of renal cell carcinoma, research is now ongoing to determine the best possible sequencing and potential combinations of those therapies. (Source: CancerNetwork)
Source: CancerNetwork - November 7, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer Source Type: news

Acid Reducers Do Not Impact VEGF Inhibitor Efficacy in Metastatic RCC
The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - November 7, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Source Type: news

Nivolumab Can Still Benefit RCC Patients Who Stop Due to Immune-Related Toxicity
A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy. (Source: CancerNetwork)
Source: CancerNetwork - November 6, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Source Type: news

Genes Influence Outcomes of Treatment Sequences in Clear Cell RCC
Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated. (Source: CancerNetwork)
Source: CancerNetwork - November 6, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Source Type: news

CRLX101/Bevacizumab Combination No Better Than Standard Care in Metastatic RCC
The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in metastatic renal cell carcinoma compared with standard of care. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Source Type: news

Cabozantinib Tops Everolimus in Advanced RCC, Regardless of MET Expression
Expression of MET as measured by immunohistochemistry was not associated with any difference in the performance of cabozantinib as compared with everolimus in patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/IKCS 2016 Kidney Cancer News Source Type: news